Arbutus Biopharma (ABUS) Proxy Filing summary

Executive summary

• The annual general meeting will be held virtually on May 21, 2025, with voting available online, by phone, or by mail.

• Shareholders will vote on the election of five directors, an advisory say-on-pay vote, and the appointment of EY as auditor.

• Proxy materials and the annual report are available online, with printed copies upon request.

• The record date for voting is March 24, 2025, with 191,480,188 common shares outstanding.

Voting matters and shareholder proposals

• Proposals include: election of five directors, advisory approval of executive compensation, and approval of EY as auditor for 2025.

• Board recommends voting FOR all director nominees and FOR both other proposals.

• Shareholders can submit proposals for the 2026 meeting by February 21, 2026 (Canada) or December 5, 2025 (US Rule 14a-8).

• Shareholders may nominate directors with proper notice and compliance with advance notice provisions.

Board of directors and corporate governance

• Board consists of five directors, four of whom are independent; CEO also serves as Chair.

• Committees: Audit, Compensation, and Corporate Governance/Nominating, all with independent members.

• Board and committee meetings were well attended in 2024; directors are encouraged to attend annual meetings.

• Corporate governance guidelines and code of conduct are in place, with regular reviews.

• Shareholders can communicate with the board via multiple channels.